Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same authorSame journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

PSMA-PET response under [<sup>177</sup>Lu]Lu-PSMA therapy: Comparison of RECIST, PERCIST, PPP, adapted PCWG4 and RECIP criteria.

European journal of nuclear medicine and molecular imaging·2026
Same author

Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901).

European urology·2026
Same author

PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617.

Radiology·2026
Same author

New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study.

The Lancet. Oncology·2026
Same author

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
查看所有相关文章

相关实验视频

Updated: Jul 24, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

前列腺特异性膜抗原报告和数据系统2.0版本

Rudolf A Werner1, Philipp E Hartrampf2, Wolfgang P Fendler3

  • 1Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany; The Russell H Morgan Department of Radiology and Radiological Science, Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

European urology
|July 6, 2023
PubMed
概括
此摘要是机器生成的。

前列腺特异性膜抗原报告和数据系统 (PSMA-RADS) 版本2.0完善了在PSMA-PET成像上检测前列腺癌的病变特征. 这一更新的框架旨在改善临床决策,克服前一个版本的局限性.

关键词:
前列腺癌的前列腺癌.前列腺特异性膜抗原.报告和数据系统报告和数据系统结构化的报告报告.

更多相关视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.9K

相关实验视频

Last Updated: Jul 24, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.9K

科学领域:

  • 核医学是一种核医学.
  • 放射性药物 放射性药物 放射性药物
  • 在瘤学瘤学.

背景情况:

  • 前列腺特异性膜抗原报告和数据系统 (PSMA-RADS) 版本1.0标准化了前列腺癌中针对PSMA的PET成像报告.
  • 证据支持PSMA-RADS 1.0类别,反映了实际的损伤阳性,并显示了各个辐射追踪器的观察者之间的高度一致.
  • 该系统有助于做出临床决策,包括管理寡头转移性疾病,但存在局限性,特别是在对治疗病变的后续评估中.

研究的目的:

  • 将PSMA-RADS框架更新到2.0.0版本
  • 引入精细的类别,以优化病变水平的表征.
  • 加强前列腺癌管理中的临床决策支持.

主要方法:

  • 对PSMA-RADS 1.0性能和局限性进行系统性审查和专家共识.
  • 开发PSMA-RADS版本2.0.0的新类别和标准.
  • 在不同临床场景中验证更新的框架.

主要成果:

  • 一般来说,PSMA-RADS 1.0类别与真正的病变阳性相关.
  • 观察者之间的高度一致性与Ga-和F-标记的PSMA追踪剂观察到.
  • 针对后续评估的PSMA-RADS 1.0中发现的局限性需要更新框架.

结论:

  • 在PSMA-PET成像中,PSMA-RADS 2.0版本为病变表征提供了一个改进的框架.
  • 更新后的系统旨在提高诊断准确性和临床实用性.
  • 在PSMA-RADS 2.0中改进的类别将更好地帮助前列腺癌的管理和治疗决策.